(Date:12/16/2009)... University (NTU) signed the Memorandum of Understanding in ... (CNRS) and the Thales Group of Companies to ... parties are meeting again in Singapore to inaugurate ... , Located at the Research Techno Plaza, ... in science and technology to develop innovations in ...
(Date:12/16/2009)... Blood America, Inc. (OTC Bulletin Board: CBAI), the ... http://www.cordblood-america.com ) focused on bringing the life ... policy, to families nationwide and internationally, said today ... total of $1.4 million so far in the ... for the year now tops $10 million. ,, ...
(Date:12/16/2009)... Protocol Assessment with the Food and Drug ... - AEterna Zentaris Inc. (NASDAQ: AEZS ... biopharmaceutical company focused on oncology and endocrine ... partner Keryx Biopharmaceuticals Inc. ("Keryx") ( KERX), ... for perifosine (KRX-0401), the Company,s PI3K/Akt pathway ...
(Date:12/15/2009)... Calif., Dec. 15 Epeius Biotechnologies Corporation, ... genetic medicine, gained international validation of the cutting-edge ... , when scientists around the world rediscovered the ... major locus of cancer pathogenesis and disease progression, ... Recently, scientists at the NIH National Cancer Institute ...
Breaking Biology Technology:New Singapore-French nanotech lab opens at NTU 2New Singapore-French nanotech lab opens at NTU 3Cord Blood America Says 2009 Debt Reduction Tops $10 Million 2Cord Blood America Says 2009 Debt Reduction Tops $10 Million 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 4AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 5Scientists Rediscover Gene Target for Cancer Therapy 2Scientists Rediscover Gene Target for Cancer Therapy 3... (Nasdaq: PRXL ), a leading global ... a Vice President and General,Manager in the ... more than 20 years of experience in ... Ms. Fisher leads a global,team of experts ...
... with Amgen- ... 9:00 A.M. EDT-, MONTVALE, N.J., March 12 ... it has realigned,its operations, reallocated its resources and extended ... The Company will,focus its near-term and mid- term efforts ...
... Utilizes Revolutionary Electrotherapy to Improve Healing ... ... 12 Kingfisher Americas,a healthcare company focused on improving patient ... Healthcare, has,received CE mark for its KFH Novo medical device, ...
Other Biology Technology:PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team 2PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team 3PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team 4Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs 2Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs 3Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs 4Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs 5Kingfisher Healthcare Receives European CE Mark for Next Generation Wound Healing Device 2Request Info...
... The Nick Translation System is ideal for ... The Nick Translation System: Provides five ... nucleotide incorporation Yields >10 8 ... control DNA to monitor the performance of ...
ABI 432 Resins • Gln(Trt) Peptide Synthesis Column...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products:Biology NavigationMedical Navigation